Silexion Therapeutics Reports First Patient Dosed in SIL204 Trial and $4.8 Million in Cash

Silexion Therapeutics dosed the first patient worldwide in its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center on September 30, 2026, and reported cash and cash equivalents of $4.8 million as of that date. The company announced the results in its third-quarter 2026 update, GlobeNewswire reported on November 13, 2026.

Silexion's SIL204 Trial Design and Site Expansion

Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers, with SIL204 as its lead candidate for locally advanced pancreatic cancer. The company initiated the Phase 2/3 trial at Tel Aviv Sourasky Medical Center on July 29, 2026, after approval from the Israeli Ministry of Health, and dosed the first patient there on September 30, 2026.

The prospective, randomized, controlled, multinational, open-label study evaluates SIL204 combined with standard-of-care chemotherapy against chemotherapy alone in newly diagnosed, treatment-naive patients with unresectable Stage 3 locally advanced pancreatic cancer whose tumors harbor a confirmed KRAS mutation. SIL204 is given through a dual-route regimen: direct EUS-guided intratumoral delivery to the primary tumor plus subcutaneous injections intended to provide systemic exposure. The study begins with a safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of approximately 166 patients.

Ilan Hadar, chairman and chief executive officer, said: "Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial." Additional Israeli oncology centers and leading academic medical institutions in Germany are progressing through site activation and are expected to join in the coming months.

Silexion's Third-Quarter Financings and Balance Sheet

According to akta.pro company records, Silexion received unconditional approval from Germany's BfArM in June 2026 and from the Israeli Ministry of Health in March 2026 to initiate the Phase 2/3 trial. The same records list a $2.5 million post-IPO equity round in August 2026 and total funding of $26.8 million.

Silexion completed a registered public offering in August 2026 with gross proceeds of approximately $2.5 million and a warrant inducement transaction in September 2026 with gross proceeds of approximately $0.84 million, and continued sales under its at-the-market facility for gross proceeds of approximately $1.9 million. Cash and cash equivalents stood at $4.8 million on September 30, 2026, compared with $6.0 million on December 31, 2025, and $2.2 million on June 30, 2026. Shareholders' equity was $3.0 million, compared with $2.6 million at the end of 2025.

Silexion's Path to the First Dosing

Silexion announced on August 14, 2026, that it had initiated the Phase 2/3 trial for SIL204 at Tel Aviv Sourasky Medical Center in July 2026, following regulatory approvals from Israel and Germany, Yahoo reported. On August 12, 2026, the company priced a public offering of approximately 3.85 million ordinary shares or share equivalents, together with Series E warrants, at a combined price of $0.65 per share, expected to raise approximately $2.5 million in gross proceeds, according to Seeking Alpha. Stock Titan reported on September 30, 2026, that the first patient had been dosed in the trial at Tel Aviv Sourasky Medical Center.

Silexion's Reverse Split and Next Steps

Silexion effected a 1-for-24 reverse share split on November 10, 2026, after a 1-for-10 reverse share split on May 28, 2026. The company said additional trial sites in Israel and Germany are expected to join in the coming months as it enrolls the safety run-in cohort.